Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from approved medicines such as semaglutide and tirzepatide
This has led to ethical concerns, as the increased demand helped create a shortage of these drugs around the world in recent months
Case series from clinicians prescribing these medications for obesity have documented unexpected reductions in alcohol consumption among patients with no prior indication of alcohol-related concerns
Sources Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: SURMOUNT-4 PubMed Continued Treatment With Tirzepatide for Maintenance of Weight Reduction Wegovy Prescribing Information FDA Nutritional Priorities to Support GLP-1 Therapy for Obesity Dr
Esta triple seal sobre tres dianas moleculares distintas sistema nervioso central, pncreas y tejido heptico define el perfil farmacolgico ms amplio documentado hasta la fecha en la familia de los agonistas de incretinas
Retatrutide targets three hormones
